50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
QQQ   271.87 (-2.88%)
AAPL   142.48 (-4.91%)
MSFT   237.50 (-1.48%)
META   136.41 (-3.67%)
GOOGL   97.42 (-2.63%)
AMZN   114.80 (-2.72%)
TSLA   268.21 (-6.81%)
NVDA   122.20 (-4.05%)
NIO   15.58 (-10.10%)
BABA   79.06 (-2.38%)
AMD   64.14 (-6.17%)
T   15.53 (-1.90%)
MU   50.01 (-1.94%)
CGC   2.78 (-8.55%)
F   11.47 (-5.83%)
GE   62.73 (-2.68%)
DIS   97.45 (-1.96%)
AMC   7.10 (-7.43%)
PYPL   88.70 (-2.66%)
PFE   44.16 (-0.61%)
NFLX   239.71 (-2.24%)
NASDAQ:NLSP

NLS Pharmaceutics - NLSP News Today

$0.70
-0.03 (-4.13%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.65
$1.00
50-Day Range
$0.35
$1.12
52-Week Range
$0.33
$2.83
Volume
383,040 shs
Average Volume
1.24 million shs
Market Capitalization
$8.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.



NLSP Media Mentions By Week

NLSP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NLSP
News Sentiment

0.96

0.80

Average
Medical
News Sentiment

NLSP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NLSP Articles
This Week

7

1

NLSP Articles
Average Week

SourceHeadline
finance.yahoo.com logoNLS Pharmaceutics' Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors
finance.yahoo.com - September 27 at 6:57 PM
seekingalpha.com logoNLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
seekingalpha.com - September 27 at 1:57 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
finance.yahoo.com - September 27 at 8:56 AM
finance.yahoo.com logoNLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results
finance.yahoo.com - September 19 at 10:32 AM
morningstar.com logoNLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development | Morningstar
morningstar.com - September 10 at 11:16 AM
finance.yahoo.com logoNLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
finance.yahoo.com - September 8 at 9:19 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
finanznachrichten.de - July 28 at 1:35 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
finance.yahoo.com - July 28 at 1:35 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
finance.yahoo.com - July 21 at 8:54 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
finanznachrichten.de - June 10 at 9:16 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
finance.yahoo.com - June 10 at 9:16 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
finanznachrichten.de - June 6 at 11:42 AM
seekingalpha.com logoNLS Pharmaceutics appoints Chad Hellmann as CFO
seekingalpha.com - June 6 at 11:42 AM
finance.yahoo.com logoNLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
finance.yahoo.com - June 6 at 11:42 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience for the Treatment of Narcolepsy
finanznachrichten.de - June 3 at 6:18 AM
finance.yahoo.com logoNLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
finance.yahoo.com - June 2 at 10:16 AM
barrons.com logoNLS Pharmaceutics Ltd.
barrons.com - May 17 at 8:32 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience Phase 2a Clinical Trial for Patients with Narcolepsy
finanznachrichten.de - May 6 at 5:59 PM
seekingalpha.com logoNLS Pharma hits 90% enrollment target in mid-stage trial for narcolepsy candidate
seekingalpha.com - May 4 at 12:44 PM
finance.yahoo.com logoNLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
finance.yahoo.com - May 4 at 12:44 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
finanznachrichten.de - April 26 at 11:14 PM
finance.yahoo.com logoNLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
finance.yahoo.com - April 26 at 11:14 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
finanznachrichten.de - April 22 at 12:30 PM
finance.yahoo.com logoNLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
finance.yahoo.com - April 22 at 12:30 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finanznachrichten.de - April 15 at 7:39 PM
seekingalpha.com logoNLS Pharmaceutics launches $4.4M share offering
seekingalpha.com - April 13 at 1:26 PM
finance.yahoo.com logoNLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - April 13 at 1:26 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
finance.yahoo.com - April 1 at 6:03 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
finanznachrichten.de - March 31 at 9:37 AM
finance.yahoo.com logoNLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
finance.yahoo.com - March 31 at 9:37 AM
finance.yahoo.com logoNLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
finance.yahoo.com - March 28 at 6:15 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
finanznachrichten.de - March 25 at 2:21 PM
finance.yahoo.com logoNLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
finance.yahoo.com - March 25 at 2:21 PM
msn.com logoNLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
msn.com - March 16 at 4:22 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy
finanznachrichten.de - March 16 at 11:22 AM
seekingalpha.com logoNLS Pharma posts interim data from mid-stage trial for narcolepsy candidate
seekingalpha.com - March 16 at 11:22 AM
finance.yahoo.com logoNLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
finance.yahoo.com - March 16 at 11:22 AM
finance.yahoo.com logoNLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
finance.yahoo.com - February 25 at 11:26 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
finanznachrichten.de - February 11 at 9:52 AM
finance.yahoo.com logoNLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
finance.yahoo.com - February 11 at 9:52 AM
finance.yahoo.com logoWhy Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?
finance.yahoo.com - February 7 at 2:44 PM
finance.yahoo.com logoNLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
finance.yahoo.com - February 7 at 8:06 AM
nasdaq.com logoNLS Pharmaceutics Ltd Shares Approach 52-Week Low - Market Mover
nasdaq.com - January 15 at 9:47 AM
nasdaq.com logoNLS Pharmaceutics Ltd Shares Near 52-Week Low - Market Mover
nasdaq.com - January 14 at 2:43 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
finanznachrichten.de - January 12 at 10:40 AM
finance.yahoo.com logoNLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
finance.yahoo.com - January 12 at 10:40 AM
marketwatch.com logoNLS Pharmaceutics Shares Take Flight on U.S. Patent >NLSP
marketwatch.com - January 4 at 2:04 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
finanznachrichten.de - January 4 at 8:55 AM
finance.yahoo.com logoNLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
finance.yahoo.com - January 4 at 8:55 AM
nasdaq.com logoNLS Pharmaceutics Ltd. Ordinary Shares (NLSP)
nasdaq.com - December 22 at 8:51 PM
Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:NLSP) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.